Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Halo Pharma Announces Investment and Formal Collaboration with Altus

Published: Thursday, May 16, 2013
Last Updated: Thursday, May 16, 2013
Bookmark and Share
Halo Pharma has taken a minority ownership position in, and established a formal collaboration with, Altus Formulation Inc.

Altus uses proprietary technologies and approaches to solve pharmaceutical formulation and delivery problems.

Halo is focused on satisfying the pharmaceutical client's development and manufacturing needs, whether those needs are straightforward or complex. On a fee for service basis Halo will always remain committed to practical facilitation and implementation of non proprietary and client based solutions to scientific and technical challenges in the areas of pre-formulation, analytical method development, formulation, scale up, regulatory submission and commercial manufacturing. These approaches typically generate significant new wholly client owned IP.

With this new investment in, and association with, Altus Formulations, Halo takes a first step in offering to clients, when needed, an entire suite of proprietary scientific and technical solutions designed to solve intractable issues in such areas as drug solubility, bioavailability, tamper and abuse deterrence, and precisely managed drug dosage delivery. These proprietary solutions cover a wide range of non-sterile and sterile dosage forms. One such area requiring solution is the currently much discussed question of the need for abuse resistance for narcotic analgesic and other frequently abused CNS drugs.

In commenting on the collaboration with Altus the CEO of Halo Pharma Clive Bennett said, "We are delighted to have this new association with Altus as it will allow Halo to provide novel proprietary solutions to clients with difficult formulation problems in addition to those already available public domain and client originated solutions that we have historically offered."

Damon Smith CEO of Altus Formulation remarked, "The Altus team is extremely excited to be collaborating with Halo Pharma with their track record of excellence in the contract development and manufacturing fields. By combining our strengths Altus and Halo offer a full range of development and delivery options that are ideally placed to meet the needs of the industry."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Growing Stem Cells More Safely
Nurturing stem cells atop a bed of mouse cells works well, but is a non-starter for transplants to patients – Brown University scientists are developing a synthetic bed instead.
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!